• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肝细胞癌中与二硫化物驱动细胞死亡和免疫浸润相关的预后风险模型的建立。

Establishment of prognostic risk model related to disulfidptosis and immune infiltration in hepatocellular carcinoma.

作者信息

Xu Zhe, Pang Chong, Xu Xundi

机构信息

Department of Breast and Thyroid Surgery, South China Hospital, Medical School, Shenzhen University, Shenzhen, 518116, PR China.

Department of Hepatobiliary Pancreatic Surgery, South China Hospital, Medical School, Shenzhen University, Shenzhen, 518116, PR China.

出版信息

Heliyon. 2024 Nov 14;10(23):e40405. doi: 10.1016/j.heliyon.2024.e40405. eCollection 2024 Dec 15.

DOI:10.1016/j.heliyon.2024.e40405
PMID:39687103
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11647807/
Abstract

BACKGROUND

Disulfidptosis is a newly discovered type of cell death. We aim to identify hub genes associated with both disulfidptosis and immune infiltration in hepatocellular carcinoma (HCC) patients, and to develop an individualized risk prediction model.

METHODS

The TCGA-LIHC cohort was utilized as the training set to identify molecular subtypes associated with disulfidptosis and to perform immune infiltration analysis. WGCNA, univariate Cox, and LASSO algorithm were employed to select hub genes for constructing the prognostic model. ICGC-LIRI cohort was utilized as an independent testing set. Validation of the expression of hub genes was performed using qRT-PCR and Western blot.

RESULTS

Cluster 1 was identified as the disulfidptosis associated molecular subtype, characterized by higher expression of disulfidptosis related genes (DRGs) and immune infiltration levels. ANXA2, MSC, and ST6GALNAC4 were identified as hub genes for calculating the risk score. The high-risk group were more likely to benefit from immunotherapy, targeted therapy and chemotherapy. A prognostic model was developed combining clinicopathological factors with satisfactory predictive accuracy. The hub genes were found upregulated in HCC cell line.

CONCLUSIONS

Our findings provide valuable theoretical support for prognostic prediction and the evaluation of therapeutic outcomes in relation to disulfidptosis and immune infiltration in HCC, highlighting the importance of conducting in-depth research on disulfidptosis-related mechanisms.

摘要

背景

二硫化物诱导的细胞死亡是一种新发现的细胞死亡类型。我们旨在鉴定与肝细胞癌(HCC)患者的二硫化物诱导的细胞死亡和免疫浸润相关的枢纽基因,并建立个性化风险预测模型。

方法

将TCGA-LIHC队列用作训练集,以鉴定与二硫化物诱导的细胞死亡相关的分子亚型并进行免疫浸润分析。采用加权基因共表达网络分析(WGCNA)、单变量Cox分析和套索(LASSO)算法选择枢纽基因来构建预后模型。将ICGC-LIRI队列用作独立测试集。使用qRT-PCR和蛋白质免疫印迹法对枢纽基因的表达进行验证。

结果

聚类1被鉴定为与二硫化物诱导的细胞死亡相关的分子亚型,其特征是二硫化物诱导的细胞死亡相关基因(DRGs)表达较高且免疫浸润水平较高。鉴定出膜联蛋白A2(ANXA2)、间充质干细胞(MSC)和N-乙酰神经氨酸α-2,6-唾液酸转移酶4(ST6GALNAC4)作为计算风险评分的枢纽基因。高危组更有可能从免疫治疗、靶向治疗和化疗中获益。结合临床病理因素建立了一个预后模型,其预测准确性令人满意。发现枢纽基因在肝癌细胞系中上调。

结论

我们的研究结果为HCC中与二硫化物诱导的细胞死亡和免疫浸润相关的预后预测及治疗效果评估提供了有价值的理论支持,突出了对二硫化物诱导的细胞死亡相关机制进行深入研究的重要性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/032f/11647807/2ee6c3277e4a/gr9.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/032f/11647807/c4ad46225356/ga1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/032f/11647807/1e5df43b06f8/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/032f/11647807/92bef15fd80c/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/032f/11647807/63e7740e661d/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/032f/11647807/f0f5fb0d1ce2/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/032f/11647807/e5e27ac3f62c/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/032f/11647807/4c6b1533168f/gr6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/032f/11647807/941a612c3dff/gr7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/032f/11647807/2831c9150d23/gr8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/032f/11647807/2ee6c3277e4a/gr9.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/032f/11647807/c4ad46225356/ga1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/032f/11647807/1e5df43b06f8/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/032f/11647807/92bef15fd80c/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/032f/11647807/63e7740e661d/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/032f/11647807/f0f5fb0d1ce2/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/032f/11647807/e5e27ac3f62c/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/032f/11647807/4c6b1533168f/gr6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/032f/11647807/941a612c3dff/gr7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/032f/11647807/2831c9150d23/gr8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/032f/11647807/2ee6c3277e4a/gr9.jpg

相似文献

1
Establishment of prognostic risk model related to disulfidptosis and immune infiltration in hepatocellular carcinoma.肝细胞癌中与二硫化物驱动细胞死亡和免疫浸润相关的预后风险模型的建立。
Heliyon. 2024 Nov 14;10(23):e40405. doi: 10.1016/j.heliyon.2024.e40405. eCollection 2024 Dec 15.
2
Disulfidptosis-related genes of prognostic signature and immune infiltration features in hepatocellular carcinoma supported by bulk and single-cell RNA sequencing data.基于批量和单细胞RNA测序数据的肝细胞癌中与二硫化物诱导细胞死亡相关的预后特征基因及免疫浸润特征
J Gastrointest Oncol. 2024 Feb 29;15(1):377-396. doi: 10.21037/jgo-23-949. Epub 2024 Feb 1.
3
Disulfidptosis-related signatures for prognostic and immunotherapy reactivity evaluation in hepatocellular carcinoma.二硫键相关特征可用于预测肝细胞癌的预后和免疫治疗反应。
Eur J Med Res. 2023 Dec 6;28(1):571. doi: 10.1186/s40001-023-01535-3.
4
Identification and characterization of a novel molecular classification based on disulfidptosis-related genes to predict prognosis and immunotherapy efficacy in hepatocellular carcinoma.基于二硫键凋亡相关基因的新型分子分类鉴定及其在肝细胞癌中的预后和免疫治疗疗效预测
Aging (Albany NY). 2023 Jul 3;15(13):6135-6151. doi: 10.18632/aging.204809.
5
Disulfidptosis related immune genes drive prognostic model development and tumor microenvironment characterization in bladder urothelial carcinoma.二硫化物诱导细胞程序性坏死相关免疫基因推动膀胱尿路上皮癌预后模型的建立及肿瘤微环境特征分析
Sci Rep. 2025 Mar 8;15(1):8130. doi: 10.1038/s41598-025-92297-x.
6
Constructing a disulfidptosis-related prognostic signature of hepatocellular carcinoma based on single-cell sequencing and weighted co-expression network analysis.基于单细胞测序和加权共表达网络分析构建肝细胞癌的二硫键失调相关预后签名。
Apoptosis. 2024 Oct;29(9-10):1632-1647. doi: 10.1007/s10495-024-01968-z. Epub 2024 May 17.
7
Construction of a novel disulfidptosis-related signature for improving outcomes in hepatocellular carcinoma: Observational study.构建一种新型的与二硫键相关的标志物,以改善肝细胞癌的预后:观察性研究。
Medicine (Baltimore). 2023 Oct 6;102(40):e35423. doi: 10.1097/MD.0000000000035423.
8
Disulfidptosis classification of hepatocellular carcinoma reveals correlation with clinical prognosis and immune profile.肝细胞癌的二硫键蛋白组学分类揭示了与临床预后和免疫特征的相关性。
Int Immunopharmacol. 2023 Jul;120:110368. doi: 10.1016/j.intimp.2023.110368. Epub 2023 May 27.
9
Novel application of the ferroptosis-related genes risk model associated with disulfidptosis in hepatocellular carcinoma prognosis and immune infiltration.与二硫化物诱导的细胞死亡相关的铁死亡相关基因风险模型在肝细胞癌预后和免疫浸润中的新应用
PeerJ. 2024 Feb 2;12:e16819. doi: 10.7717/peerj.16819. eCollection 2024.
10
A novel signature incorporating lipid metabolism- and immune-related genes to predict the prognosis and immune landscape in hepatocellular carcinoma.一种包含脂质代谢和免疫相关基因的新型特征,用于预测肝细胞癌的预后和免疫格局。
Front Oncol. 2023 Jun 6;13:1182434. doi: 10.3389/fonc.2023.1182434. eCollection 2023.

本文引用的文献

1
Molecular landmarks of tumor disulfidptosis across cancer types to promote disulfidptosis-target therapy.跨癌症类型的肿瘤二硫键凋亡分子标志物促进二硫键凋亡靶向治疗。
Redox Biol. 2023 Dec;68:102966. doi: 10.1016/j.redox.2023.102966. Epub 2023 Nov 19.
2
Effect of infiltrating immune cells in tumor microenvironment on metastasis of hepatocellular carcinoma.肿瘤微环境中浸润免疫细胞对肝癌转移的影响。
Cell Oncol (Dordr). 2023 Dec;46(6):1595-1604. doi: 10.1007/s13402-023-00841-6. Epub 2023 Jul 6.
3
FBXW10-S6K1 promotes ANXA2 polyubiquitination and KRAS activation to drive hepatocellular carcinoma development in males.
FBXW10-S6K1 促进 ANXA2 多泛素化和 KRAS 激活,从而驱动男性肝细胞癌的发展。
Cancer Lett. 2023 Jul 10;566:216257. doi: 10.1016/j.canlet.2023.216257. Epub 2023 Jun 3.
4
TKIs in combination with immunotherapy for hepatocellular carcinoma.酪氨酸激酶抑制剂联合免疫疗法治疗肝细胞癌。
Expert Rev Anticancer Ther. 2023 Mar;23(3):279-291. doi: 10.1080/14737140.2023.2181162. Epub 2023 Feb 26.
5
Actin cytoskeleton vulnerability to disulfide stress mediates disulfidptosis.细胞骨架对二硫键压力的脆弱性介导了二硫键细胞凋亡。
Nat Cell Biol. 2023 Mar;25(3):404-414. doi: 10.1038/s41556-023-01091-2. Epub 2023 Feb 6.
6
A novel prognostic index of stomach adenocarcinoma based on immunogenomic landscape analysis and immunotherapy options.基于免疫基因组景观分析和免疫治疗选择的胃腺癌新型预后指标。
Exp Mol Pathol. 2022 Oct;128:104832. doi: 10.1016/j.yexmp.2022.104832. Epub 2022 Sep 17.
7
A targetable LIFR-NF-κB-LCN2 axis controls liver tumorigenesis and vulnerability to ferroptosis.一个可靶向的 LIFR-NF-κB-LCN2 轴控制肝肿瘤发生和对铁死亡的易感性。
Nat Commun. 2021 Dec 17;12(1):7333. doi: 10.1038/s41467-021-27452-9.
8
Immunotherapies for hepatocellular carcinoma.肝细胞癌的免疫疗法
Nat Rev Clin Oncol. 2022 Mar;19(3):151-172. doi: 10.1038/s41571-021-00573-2. Epub 2021 Nov 11.
9
Cystathionine β-synthase mediated PRRX2/IL-6/STAT3 inactivation suppresses Tregs infiltration and induces apoptosis to inhibit HCC carcinogenesis.胱硫醚β-合酶介导的 PRRX2/IL-6/STAT3 失活抑制 Tregs 浸润并诱导细胞凋亡抑制 HCC 发生。
J Immunother Cancer. 2021 Aug;9(8). doi: 10.1136/jitc-2021-003031.
10
miRNA-Based Signature Associated With Tumor Mutational Burden in Colon Adenocarcinoma.与结肠腺癌肿瘤突变负荷相关的基于微小RNA的特征
Front Oncol. 2021 Jun 23;11:634841. doi: 10.3389/fonc.2021.634841. eCollection 2021.